JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, published by Elsevier, stands as a premier journal in the fields of Genetics and Health, Toxicology and Mutagenesis, boasting a Q1 ranking in both categories for 2023. With an impressive impact factor and rigorous peer-review process, this journal serves as a vital platform for disseminating cutting-edge research and comprehensive reviews regarding the implications of genetic mutations and related health effects. Established in the Netherlands, it has evolved from its inception in the early 1990s to become an essential resource for researchers, professionals, and students alike, facilitating advancements in the understanding of mutation research. Despite not offering an open-access model, the journal ensures a wide reach through institutional subscriptions, emphasizing its commitment to fostering scholarly dialogue and promoting significant findings within the scientific community.

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, published by Wiley, stands at the forefront of research dedicated to the intricate relationship between genetics and neuropsychiatric disorders. With an impressive scope that bridges various disciplines, this journal serves as a premier platform for groundbreaking studies and innovative perspectives in the fields of Cellular and Molecular Neuroscience, Genetics, and Psychiatry and Mental Health. Featuring a robust impact factor and categorized in the Q1 and Q2 quartiles across multiple relevant categories, the journal has successfully positioned itself as a leading source of high-quality research, ranking 52nd in Cellular and Molecular Neuroscience, 37th in Clinical Genetics, and 157th in Psychiatry and Mental Health within Scopus. Since its inception in 1995, it has sustained a commitment to fostering scholarly excellence and advancing our understanding of the genetic underpinnings of mental health. The journal is poised to continue its mission until 2024 and offers open access options, facilitating wider dissemination of vital knowledge among researchers, healthcare professionals, and students alike.

MOLECULAR HUMAN REPRODUCTION, published by Oxford University Press, is a pivotal journal dedicated to advancing the field of reproductive biology. Since its inception in 1995, the journal has been recognized for its rigorous peer-reviewed research and substantial contributions to the understanding of molecular mechanisms underlying human reproduction. With an impressive impact factor and ranked within the top tiers (Q1 and Q2) across diverse categories including Embryology, Obstetrics and Gynecology, and Reproductive Medicine, it stands as an essential resource for researchers, healthcare professionals, and students alike. The journal aims to publish cutting-edge research that explores the complexities of human reproduction at the molecular and cellular levels, fostering a deeper understanding that can be translated into clinical practice. Although it currently operates under a subscription model, the valuable insights and groundbreaking findings featured within its pages continue to influence the trajectory of reproductive health research globally. Located in the heart of Oxford, United Kingdom, the journal remains committed to addressing vital challenges in the field and promoting innovative scientific dialogue.

Aging-US is a premier peer-reviewed journal dedicated to advancing the field of aging research and cell biology. Published by IMPACT JOURNALS LLC, this journal serves as a vital resource for researchers and professionals exploring the biological mechanisms of aging and their implications for health and disease. With a commendable impact factor reflected in its 2023 Scopus rankings, where it stands at Rank #10/38 in the category of Aging and Rank #63/285 in Cell Biology, Aging-US exemplifies rigorous scientific excellence. Its open access policy enhances accessibility, fostering a wider dissemination of knowledge in both academic and clinical settings. Spanning from 2009 to 2024, the journal provides a platform for groundbreaking studies and innovative methodologies, ensuring that it remains at the forefront of the dynamic conversations surrounding aging and cellular biology. Engage with Aging-US to contribute to the evolving narratives of longevity and cellular health.

Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.

CURRENT GENOMICS is a premier journal published by Bentham Science Publishers that focuses on the expansive field of genomics, including both clinical and molecular genetics. With the ISSN 1389-2029 and E-ISSN 1875-5488, this esteemed journal has been disseminating significant scientific insights since its inception in 2000 and continues to contribute to the field through 2024. Based in the United Arab Emirates, CURRENT GENOMICS boasts a Q3 ranking in both the genetics and clinical genetics categories for 2023, reflecting its growing impact in the scientific community. Although not an open-access journal, it provides valuable content that supports researchers and professionals in navigating the complexities of genetic research and its applications. By publishing original research articles, reviews, and case studies, CURRENT GENOMICS aims to foster a deeper understanding of genomic science and its implications for medicine, thus playing a critical role in the advancement of genetics and biomedical research.

MOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.